Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma - LARVOL DELTA

Delgocitinib in dermatology: a topical pan-JAK inhibitor for chronic hand eczema and atopic dermatitis. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Anzupgo (delgocitinib cream) Now Available in Canada for Adult Patients Living with Moderate to Severe Chronic Hand Eczema (Canada Newswire) - "Canada's Drug Agency (CDA-AMC) issued a positive recommendation in favour of the reimbursement of Anzupgo (delgocitinib cream) for the treatment of moderate to severe chronic hand eczema (CHE) in adult patients for whom topical corticosteroids are inadequate or are not advisable. In the DELTA FORCE clinical trials, treatment with Anzupgo (delgocitinib cream) showed superior efficacy and a more favourable safety profile versus oral alitretinoin over 24 weeks."

Reimbursement • Dermatology

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. (PubMed, Int J Mol Sci) - "Taken together, these findings suggest that t-JAKi may represent safer alternatives to s-JAKi for selected patients with localized inflammatory skin diseases, particularly those with comorbidities or heightened systemic risk. Long-term studies and real-world evidence are needed to confirm sustained safety and guide their optimal integration into clinical practice."

Adverse events • Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Respiratory Diseases

Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib. (PubMed, Drugs) - "Beyond chronic hand eczema, topical delgocitinib has shown efficacy in atopic dermatitis, and preliminary evidence is emerging in other inflammatory skin diseases, including vitiligo, lichenoid dermatoses, and hair disorders. This review provides an updated overview of the biological rationale for pan-Janus kinase inhibition, summarizes the most recent outcomes of topical delgocitinib in chronic hand eczema and atopic dermatitis management, and outlines its potential new applications in the landscape of immune-mediated skin diseases."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pain • Vitiligo

Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We attempted to contribute to the existing CHE literature by producing comparative information on its treatments' relative efficacy; moreover, we found no published NMA study on available treatments for CHE before the conduct of our work. Our results can guide clinical decision-making."

Journal • Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Topical delgocitinib and dupilumab in patients with AHE had comparable efficacy, with all results being numerically in favour of delgocitinib, although not statistically significant."

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness and Safety of Delgocitinib Cream in Pustulosis Palmoplantaris: A Case Series. (PubMed, Acta Derm Venereol) - No abstract available

Journal • Immunology

Cost-Effectiveness of Delgocitinib vs. PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema (ISPOR-EU 2025) - "OBJECTIVES: Delgocitinib cream and psoralen with ultraviolet A (PUVA) light therapy are treatment options for patients with moderate or severe Chronic Hand Eczema (CHE) which has not adequately responded to treatment with topical corticosteroids...Efficacy and utility evidence for delgocitinib were derived from the DELTA 1, DELTA 2 clinical trials versus vehicle cream, and DELTA FORCE clinical trial versus alitretinoin... For treatment of patients with moderate-to-severe CHE which is inadequately treated by topical corticosteroids, delgocitinib cream provides both better clinical outcomes and lower costs for the healthcare payer in comparison with PUVA in the UK healthcare context."

Clinical • Cost effectiveness • HEOR • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Accelerating Therapeutic Innovation: Early Results From France's Accès Direct Scheme (ISPOR-EU 2025) - "Comparators were those defined by HAS. Five medicines entered the scheme: delgocitinib, danicopan, ruxolitinib, recombinant adjuvanted herpes zoster vaccine, and etranacogene dezaparvovec...At the time of analysis, two medicines remained within the program (<179 days).Price analyses showed coherent costs: €163.24 for herpes zoster vaccine and €70.00 for 100g of ruxolitinib cream (vs. €90.00 and no HAS-identified comparators respectively). The small number of medicines included and initial rejection of etranacogene dezaparpovec may reflect selection bias favoring suitable candidates... The small number of medicines included and initial rejection of etranacogene dezaparpovec may reflect selection bias favoring suitable candidates. However, preliminary findings suggest that "Accès Direct" effectively reduces time to reimbursement and improves patient access. While the scheme allows earlier funding, pricing remains similar or higher than comparators."

Dermatology • Gene Therapies • Herpes Zoster • Infectious Disease • Rare Diseases • Varicella Zoster

Comparative Efficacy and Safety of Delgocitinib, Alitretinoin, and PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema: A Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: Delgocitinib cream, alitretinoin, and psoralen with ultraviolet A (PUVA light therapy) are treatments used amongst patients with Chronic Hand Eczema (CHE) which has not adequately responded to topical corticosteroids alone. Due to limitations of available data, assumptions were required related to comparability of the IGA-CHE and PGA severity assessment tools, disease severity, treatments and outcome assessment timepoints, and the use of non-responder imputation. Notwithstanding these assumptions, amongst patients with moderate/severe CHE, treatment with delgocitinib cream is associated with both higher rates of treatment response and lower rates of discontinuation due to adverse events than either alitretinoin or PUVA light therapy."

Retrospective data • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate (Businesswire) - "The NICE committee concluded that delgocitinib cream is an effective treatment for improving symptoms of CHE, based on robust clinical evidence from the DELTA 1, 2, 3 and DELTA FORCE trials."

NICE • Atopic Dermatitis

Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema. (PubMed, Ann Med Surg (Lond)) - "Adverse events are generally mild, including application site reactions, nasopharyngitis, and headache, with caution advised in pregnancy, lactation, chronic infection, and immunosuppression. Delgocitinib offers a novel, effective, and safer alternative in CHE management, warranting further research on pediatric use, long-term outcomes, and cost-effectiveness."

Clinical • FDA event • Journal • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Infectious Disease • Pain • Pediatrics • IFNG • IL13 • IL17A • IL22 • IL4 • JAK1 • TYK2

DELTA TEEN Phase 3 Trial for Delgocitinib Cream, a non steroidal pan-JAK inhibitor, Demonstrates Efficacy and Safety in Adolescents with Moderate to Severe Chronic Hand Eczema (ISAD-RAJKA 2025) - P3 | "Few AEs assessed as probably or possibly related to the trial drug and AEs leading to withdrawal from trial or permanent discontinuation were reported, with numerically lower rates for delgocitinib cream (7.76 and 7.76 events per 100 PYO) than cream vehicle (36.68 and 12.23 events per 100 PYO). Delgocitinib cream 20 mg/g demonstrated superior efficacy compared to cream vehicle and was well tolerated in adolescents with moderate to severe CHE, with no safety concerns identified over 16 weeks of treatment."

Clinical • P3 data • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation

Key data to be presented at the 2025 Fall Clinical Dermatology Conference by LEO Pharma include (Businesswire) - "The first U.S. prevalence data on CHE, based on a survey of more than 10,000 people. The CHECK study includes findings on demographics, disease severity, healthcare resource utilization, and ability to work among CHE patients; New health economics and outcomes data that explores the burden of CHE in the U.S. and analyzes the potential financial impact of ANZUPGO (delgocitinib) cream on a U.S. Commercial Health plan; Real-world ADBRY (tralokinumab-ldrm) data, evaluating the safety and effectiveness of up to 12 months of treatment for patients with moderate to severe AD; New findings examining the burden of GPP in the U.S., as well as the effect of treatments such as SPEVIGO (spesolimab)."

Clinical data • Atopic Dermatitis • Pustular Psoriasis

Randomized Controlled Trial of the Topical JAK Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. (PubMed, J Invest Dermatol) - "Delgocitinib cream resulted in an improvement in the transcriptomic profile of lesions and may have potential as a topical treatment for FFA."

Clinical • Journal • Alopecia • Fibrosis • Immunology • CXCL10 • CXCL9 • IFNG

LEO Pharma continues global rollout of Anzupgo (delgocitinib) cream with submission of New Drug Application in China (LEO Pharma Press Release) - "The NDA submission is supported by results from DELTA China, a phase 3 trial with Anzupgo (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of Chinese adult patients with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate...Furthermore, the submission is also backed by the full clinical program of delgocitinib, which includes data from DELTA 1, 2 and 3, DELTA Force and DELTA Teen....The regulatory review process is expected to conclude in 2027."

China filing • Dermatology

Chronic hand eczema treatment with topical delgocitinib cream. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Delgocitinib cream (Anzupgo) for chronic hand eczema. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology

The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Aalborg University

New trial • Pain

INDIVIDUAL ARTICLE: The Utility of Delgocitinib in Chronic Hand Eczema. (PubMed, J Drugs Dermatol) - "Comparative studies suggest delgocitinib offers superior or similar benefits to systemic therapies like the oral retinoid alitretinoin and the biologic dupilumab, with negligible systemic exposure. These findings support delgocitinib cream as an innovative and promising topical therapy addressing a critical unmet need in CHE patient management."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials. (PubMed, Am J Clin Dermatol) - "Delgocitinib cream exhibited a favorable safety profile in both trials. These results suggest that delgocitinib cream is a treatment option for the relief of clinical signs and symptoms among patients with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate."

Journal • P3 data • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation • Pain

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema (clinicaltrials.gov) - P3 | N=362 | Completed | Sponsor: LEO Pharma | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Treatment with delgocitinib cream is associated with a reduction of Staphylococcus aureus density and pain in patients with mild to severe Chronic Hand Eczema (EADV 2025) - P2 | "In patients with mild to severe CHE, S. aureus density was positively correlated to disease severity as well as HESD pain. Treatment with delgocitinib cream at a dose of 20 mg/g for 16 weeks was associated with a significant reduction in S. aureus density."

Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Pain

Treatment with delgocitinib cream is associated with a reduction of Staphylococcus aureus density and pain in patients with mild to severe Chronic Hand Eczema (EADV 2025) - No abstract available

Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Pain

A Case of Milia-like Calcinosis Cutis Complicated by Syringoma in Down Syndrome (EADV 2025) - "She had previously been treated with a topical corticosteroid for one week without improvement, followed by delgocitinib ointment for three weeks, also without effect... To our knowledge, this is the first reported case in which MICC appeared along with syringoma on the periorbital region. The present case suggests that MICC potentially occurs in association with syringoma. Therefore, we propose the disease synonym "milia-like dystrophic calcinosis cutis" instead of MICC for the cases with milia-like carcinosis cutis associated with other diseases."

Clinical • Dermatology • Developmental Disorders • Genetic Disorders • Metabolic Disorders • Mood Disorders